Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 963-970

  Richards, Donald A ^a,c   Loesch, David ^b,c   Vukelja, Svetislava J ^a,c   Wu, Hillary ^b,c   Hyman, William J ^a,c   Nieves, Jeffery ^c   Wang, Yunfei ^c   Hu, Simin ^d   Shonukan, Oluwatoyin O ^d   Tai, Datchen F ^d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c US Oncology Research Inc   (United States)

^d Lilly USA   (United States)

Author keywords

Chemotherapy; Pegylated liposomal doxorubicin; Pemetrexed; Phase I; Solid tumors

Indexed keywords

CYANOCOBALAMIN; DOXORUBICIN; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; MACROGOL DERIVATIVE;

ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLOPIAN TUBE CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; LACRIMATION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE DISEASE; VOMITING; AGED; BREAST TUMOR; CANCER GRADING; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; MALE; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PERITONEUM TUMOR; TREATMENT OUTCOME; UTERINE TUBE TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84856067107     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9414-6     Document Type: Article

References (24)

1. Shih C, Chen VJ, Gossett LS et al (1997) LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123
2. Sun X, Cross JA, Bognar AL et al (2001) Folate-binding triggers the activation of folylpolyglutamate synthetase. J Mol Biol 310:1067-1078
3. Zhao R, Babani S, Gao F et al (2000) The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 6:3687-3695
4. Goldman ID, Zhao R (2002) Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 29:3-17
5. Fossella FV, Gatzemeier U (2000) Phase I trials of pemetrexed. Semin Oncol 29:8-16
6. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436
7. Zalipsky S (1995) Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Delivery Rev 16:157-182
8. Adriamycin (doxorubicin HCl) for injection, USP: Package insert. 10/06 update. http://www.bedfordlabs.com/BedfordLabsWeb/products/inserts/ADR-P01.pdf
9. Papahadjopoulos D, Allen TM, Gabizon A et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464
10. Gabizon A, Horowitz AT, Goren D et al (2003) In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9:6551-6559
11. Symon Z, Peyser A, Tzemach D et al (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72-78
12. Miller DS, Blessing JA, Krasner CN et al (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27:2686-2691
13. Vergote I, Calvert H, Kania M et al (2009) A randomized, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 45:1415-1423
14. Hsu DS, Balakumaran BS, Acharya CR et al (2007) Pharmaco-genomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350-4357
15. Teicher BA, Alvarez E, Liu P et al (1999) MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 26:55-62
16. Teicher BA, Chen V, Shih C et al (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016-1023
17. Schultz M, Dempsey JA (2001) Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res 21:3209-3214
18. Harris KA, Harney E, Small EJ (2002) Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. Clin Prostate Cancer 1:37-41
19. O'Shaughnessy JA (2002) Pemetrexed: an active new agent for breast cancer. Semin Oncol 29:57-62
20. O'Shaughnessy JA, Liepa AM, Nguyen B (2002) Symptom improvement with pemetrexed for heavily pre-treated patients with advanced breast cancer. Breast Cancer Res Treat 76(suppl 1):S133
21. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v3.0. 8/06 update. http://ctep. cancer.gov/reporting/ctc.html
22. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
23. Alimta® (pemetrexed disodium) injection, powder, lyophilized, for solution for intravenous use. Package insert. 7/09 update. http://pi.lilly.com/ us/alimta-pi.pdf
24. Doxil® (doxorubicin HCl liposome injection) for intravenous infusion: Full prescribing information. 5/07 update. http://www.orthobiotech.com/ orthobiotech/shared/OBI/PI/DOXIL-PI.pdf